Гидреа Drug photo

The description is actual on 04.07.2016

  • Latin name: Hydrea
  • ATH code: L01XX05
  • Active ingredient: Gidroksikarbamid (Hydroxycarbamide)
  • Producer: Bristol-Myers Squibb (USA); Bristol-Myers Squibb S.r.L. (Italy)


Hydrox carbamide, citric acid, monohydrate of lactose, hydrosodium phosphate, magnesium stearate, gelatin, titanium dioxide, iron dye.

Release form

Capsules gelatinous 500 mg in the blister packaging in a cardboard pack No. 20 or in a dark glass bottle in a cardboard pack No. 100.

Pharmacological action


Pharmacodynamics and pharmacokinetics


Gidroksikarbamid is an antimetabolite — the cytostatic fazospetsifichny drug operating in a certain phase of a cellular cycle. Drug blocks growth of tumor cells in the phase G1-S and increases synergy sensitivity of tumor cells at at the same time carried out radiation therapy. Drug of Gidrea suppresses synthesis of DNA, and the squirrel does not exert impact on synthesis of RNA.


Drug is quickly soaked up from a gastrointestinal tract, reaching within 2 hours of the maximum concentration in a blood plasma. Meal does not exert impact on absorbability of drug. It is characterized by fast distribution on fabrics and liquids of an organism, gets through GEB, into milk, collects in erythrocytes and leukocytes. Drug is metabolized in a liver. The elimination half-life makes about 4 hours. It is removed through kidneys, both in an invariable look, and in the form of urea, and also through respiratory tracts in the form of dioxide carbon.

Indications to use

  • Myelosis;
  • sickemia;
  • Osler's disease;
  • essential trombotsitemiya;
  • acute leukosis;
  • acute erythremia and erythroleukosis;
  • osteomyelofibrosis;
  • melanoma;
  • tumors of the head and neck (together with radiation therapy);
  • cancer of a neck of uterus, ovary, placenta, mammary gland (together with radiation therapy);
  • new growths of a colon, rectum, rectosigmoid connection;
  • skin melanoma.


High sensitivity to drug, pregnancy and a lactation, thrombocytopenia, a leukopenia, age till 12 years, anemia in a severe form, diseases of livers/kidneys, the patient, after chemotherapy or radiotheraphy, a lactose intolerance, deficit of lactase.

Side effects

Are shown by symptomatology of dysfunctions and diseases of various bodies and systems of an organism: anemia, leukopenia, nausea, vomiting, lock, anorexia, hyperemia, peeling and makulopapulezny enanthesis, hyperpegmentation, atrophy of nails, skin allergic reactions, headache, increased fatigue, dizziness, disorientation, drowsiness, spasms, ischuria, febricula, fever, asthma, fever.

Gidrea, application instruction (Way and dosage)

Treatment is carried out by periodic courses, under careful control of the doctor. The dosage of drug and the scheme of reception depends on a look and a form of a disease, weight of a current and a condition of the patient. On average, the initial daily dosage makes 20-40 mg/kg which is accepted at one time. The maintenance dose varies within 10-30 mg/kg a day.

The exact dosage is calculated proceeding from the actual body weight. Efficiency of treatment is determined by results of half-month term of administration of drug. In the absence of effect drug is cancelled. At its existence, administration of drug can continue during the long period. At development of anemia administration of drug can be not stopped, but in this case it is necessary to carry out a packed red cells transfusion. At a concomitant use of drug and carrying out radiation therapy side effects can amplify.


At long administration of drug in the doses exceeding recommended therapeutic patients can have signs of acute dermatological toxicity: generalized intensive hyperpegmentation of skin, violet erythema, hypostasis, stomatitis, peeling of skin of palms and feet.


At a concomitant use of drug with antidepressants, sedative, antihistaminic, narcotic, HP hypnotic drugs, alcohol, efficiency of Gidrea decreases. Reception of Cytarabinum strengthens effect of drug. At reception of Gidrea with a methotrexate and 5-fluorouratsily their efficiency decreases.

Terms of sale

According to the recipe.

Storage conditions

At a temperature of 15 — 25 °C.

Period of validity

5 years.

Analogs of Gidrea

Coincidence on the ATH code of the 4th level:

Gidroksikarbamid Medak, Biosupressin, Gidroksiurea, Gidroksiurea-Apo.

About Gidrea

Medicine of Gidrea is appointed as drug of the first line of chemotherapy at patients with a myelosis for inspection and the solution of a question of treatment tactics. About drug positive that confirms its efficiency. Administration of drug allows to receive hematologic remission at 20-40% of patients, it causes fast, but short-term decrease in quantity of leukocytes. Therefore the maintenance therapy usually of 500 mg a day or 1 g was appointed.

"… After 7 days of reception of Gidrea leukocytes fell". "… On purpose for decrease in leukocytes, drank Gidrea on 500 mg and Allopyrinolum of 400 mg". It is impossible to reach cytogenetic remission (disappearance of a Ph-chromosome) this drug. It brakes a course of a disease and allows to control the increased level of leukocytes for some time.

Refusal of use of Gidrea can aggravate situation. According to reviews drug was well transferred, side effects were seldom noted, and contraindication to its appointment is the peptic ulcer in an aggravation phase. It is possible to reach an absolute recovery at a myelosis by carrying out allogenic transplantation of marrow within the first year of a disease.

This drug is considered means of the choice and "the gold standard" of treatment of an Osler's disease. For achievement of remission cytostatic therapy was carried out to a dose of 30 mg/kg a day to 2 receptions, and then it decreased half, and the maintenance dose made 500 mg — 1 g a day. At primary myelofibrosis cytostatic therapy by this drug was carried out for the purpose of stopping of a thrombocytosis and reduction of the sizes of a spleen.

Judging by responses, it was most often appointed in a daily dose from 1000 — 3000 mg, and then the maintenance therapy was also carried out. "… This drug was prescribed, it was transferred easily, the spleen began to decrease". At an essential trombotsitemiya administration of drug is directed to normalization of number of thrombocytes, but always it was effective. "... Gidrea accepted one and a half years, but thrombocytes did not decrease lower than 90". From by-effects patients noted a hair loss.


  • Gidrea of 500 mg No. 100 kapsulybristol Myers Skvibb
  • Gidrea of 500 mg No. 20 kapsulybristol Myers Skvibb

Drugstore of IFC

  • Gidrea kaps. 500 mg No. 20, Bristol-Myers Squibbitaliya
to show still


  • Gidrea of 500 mg No. 100 kaps.bristol-Myers Squibb (Italy)
to show still
Section: Antineoplastic
in more detail

Education: Graduated from Sverdlovsk medical school (1968 - 1971) as "Paramedic". Graduated from the Donetsk medical institute (1975 - 1981) as "An epidemiologist, a hygienist". Passed postgraduate study in the Central scientific research institute of epidemiology Moscow (1986 - 1989). An academic degree – the candidate of medical sciences (degree is awarded in 1989, protection – the Central scientific research institute of epidemiology Moscow). Numerous advanced training courses are studied in epidemiology and infectious diseases.

Experience: Work as the manager of department of disinfection and sterilization of 1981 - 1992. Work as the manager of department of especially dangerous infections of 1992 - 2010. Teaching activity at Medical institute 2010 - 2013.

PAY ATTENTION! Information on drugs on the website is help generalizing, collected from public sources and can form the basis for making decision on use of medicines it is not aware of treatment. Before use of medicine of Gidrea surely consult with the attending physician.